Fig. 1
Trabecular bone loss in 5XFAD mice was diminished by PTH1-34 treatments. A Schematic of hPTH1-34 or vehicle (0.9% sodium chloride) intermittent treatment and tissue samples collection in WT/5XFAD female mice. Female WT/5XFAD mice were administered a once-daily injection of hPTH1–34, or veh (0.9% NaCl) via subcutaneous injection, starting at 2 ~ MO old, 5 days per week. Mice were sacrificed at 6 ~ MO old to detect bone phenotypes. B–F μCT analysis of femurs from 6 ~ MO WT and 5XFAD female mice with PTH1-34 or Veh treatment. Representative images are shown in B and quantification analyses of trabecular bone volume over total volume (Tb. BV/TV), trabecular bone number (Tb. N), trabecular bone thickness (Tb. Th), and cortical bone volume over total volume (Cb. BV/TV) by the direct model of μCT analysis are presented in B–F. G Serum osteocalcin levels analyses, measured by ELISA assays, in 6 ~ MO female mice. H Serum PYD levels analyses, measured by ELISA assays, in 6 ~ MO female mice. Three different female mice from each group were examined. The data were presented as mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001, two-way ANOVA with two-stage step-up method of Benjamini, Krieger, and Yekutieli multiple comparisons test was used